It can help restore hormone levels while keeping the natural system intact. For those with secondary hypogonadism who want to avoid the fertility-suppressing effects and dependency of TRT, it is a very suitable option to discuss with a specialist. For a younger man, starting lifelong TRT can be a daunting prospect due to its effects on fertility and the need for continuous treatment. This is the central advantage of enclomiphene over traditional testosterone replacement therapy (TRT). So, who is the right candidate to talk about enclomiphene with a healthcare provider? Compared to clomiphene, enclomiphene appears to have fewer side effects, especially those related to mood and vision. Compared to TRT, enclomiphene's main safety advantage is the preservation of fertility and testicular size. Chronic estrogen receptor blockade, even partial, has long-term implications that are not captured in a standard hormone panel. But estrogen receptors exist throughout your entire body, not just your brain. It boosts testosterone through your own HPTA axis, preserves fertility, and offers an exit ramp that TRT does not. The combination addresses one of enclomiphene’s weaknesses while MK-677’s tendency to not affect testosterone is complemented by enclomiphene’s testosterone-boosting effect. This IGF-1 reduction is one reason some natty plus practitioners combine enclomiphene with MK-677, a growth hormone secretagogue that raises IGF-1. In one study, enclomiphene at 6.25mg and 12.5mg daily decreased IGF-1 by approximately 50 percent. There was a clear shift in the morning total testosterone values from 2). On day 1 transdermal testosterone raised the CTTmean and CTTmax, although those increases were not significant among groups; probably because of the high variation in the mean values in the subjects who were treated with transdermal testosterone. These observations were true whether the data were recorded as CTT0h, CTTmean, CTTmax, CTTmin values or as the range of total testosterone concentration (CTTrange). After daily treatment for 6 weeks, differences among treatment groups were significant according to anova. We screened men with two morning total testosterone measurements TT0h) values were determined before the drug was administered (i.e. the initial pharmacodynamics). By raising IGF-1 through GH secretagogue activity, it not only restores the IGF-1 that enclomiphene reduces but pushes it above baseline. In clinical data, enclomiphene at therapeutic doses reduced IGF-1 by approximately 50 percent. MK-677 elevates growth hormone and IGF-1 but does nothing for testosterone. The combination of MK-677 and enclomiphene has become the signature stack of the natty plus movement, and for good reason. TRT wins on raw testosterone elevation, consistency of levels, and decades of clinical data. By boosting testosterone production, Enclomiphene can help enhance energy levels, allowing individuals to feel more vibrant and active. At a high level, the existing literature suggests that enclomiphene may increase testosterone in selected men while preserving sperm counts better than exogenous testosterone in some study settings. That has kept enclomiphene highly visible across clinics, telehealth platforms, and hormone-focused patient communities.